HalfLifeDBEvidence before certainty.

MDMB-class synthetic cannabinoids evidence profile

“MDMB-class synthetic cannabinoids” is a chemical family rather than one analyte.

Category: synthetic-cannabinoid · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References2Linked studies, labels, reviews, or identity records described below

MDMB-class synthetic cannabinoids: evidence and interpretation notes

Why HalfLifeDB does not plot MDMB-class synthetic cannabinoids

“MDMB-class synthetic cannabinoids” is a chemical family rather than one analyte. A postmortem MDMB-CHMICA distribution paper cannot establish a class-wide human half-life.

MDMB-class synthetic cannabinoids are not one uniform drug. This entry uses MDMB-CHMICA-centered sources as a concrete anchor for a broader class note.

The 3 hour value is a simplified class-level placeholder, not a claim that all MDMB-related synthetic cannabinoids share the same kinetics.

The citations include post-mortem distribution research for MDMB-CHMICA and the direct compound record.

The page does not generalize safety, potency, or detectability across synthetic cannabinoid products.

For MDMB-class synthetic cannabinoids, class-level uncertainty is the main limitation. Synthetic cannabinoid chemistry varies widely, so this page should be treated as a narrow educational anchor.

What each source contributes

  • Kronstrand R et al. Post-mortem distribution of MDMB-CHMICA and metabolites (2018). This case record documents an observed clinical or forensic exposure and cannot define a controlled population value.
  • PubChem: MDMB-CHMICA. This identity record confirms names and compound identity and does not supply a human half-life.

For MDMB-class synthetic cannabinoids, the decision to withhold a curve turns on the limits visible in Kronstrand R et al. Post-mortem distribution of MDMB-CHMICA and metabolites (2018). This case record documents an observed clinical or forensic exposure, but it cannot define a controlled population value.

What evidence would change the page

The publication threshold for a future MDMB-class synthetic cannabinoids model is concrete: serial human plasma data, explicit analyte identification, a described route or preparation, and a reported half-life phase. Kronstrand R et al. Post-mortem distribution of MDMB-CHMICA and metabolites (2018) remains useful, but it does not cross that threshold.

InterpretationCategory context and evidence limits

synthetic cannabinoid context

Synthetic cannabinoid entries can have sparse human pharmacokinetic evidence, active metabolites, and toxicology-focused sources that make uncertainty especially important.

  • Half-life is not a safety, potency, or impairment estimate.
  • Evidence quality may differ substantially between compounds.
  • Metabolite and testing questions require specific source context.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

1 PubMed0 PMC0 DailyMed1 PubChem
  1. Research abstract Kronstrand R et al. Post-mortem distribution of MDMB-CHMICA and metabolites (2018).
    Forensic or clinical case evidence. It documents an observed exposure but does not define typical controlled human pharmacokinetics.
  2. Identity record PubChem Compound Summary: MDMB-CHMICA.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.